In CEO David Ricks' first year running the show, Eli Lilly posted nearly 8% revenue growth to $22.87 billion, beating the high end of its own guidance of $22.7 billion set in the third-quarter report.
Erectile dysfunction blockbuster Cialis was on FiercePharma’s patent expiration list last year, but Eli Lilly managed to score a few more months of exclusivity in a July settlement with multiple generic drugmakers.
